key: cord-1055200-ho7f58kc
authors: Baj, Andreina; Novazzi, Federica; Ferrante, Francesca D.; Genoni, Angelo; Cassani, Gianluca; Prestia, Martina; Colombo, Alberto; Capuano, Riccardo; Zago, Christian; Pasciuta, Renee; Tamborini, Antonio; Rossi, Agostino; Tettamanzi, Elena; Catanoso, Giuseppe; Focosi, Daniele; Maffioli, Lorenzo; Maggi, Fabrizio
title: Introduction of SARS‐COV‐2 C.37 (WHO VOI lambda) from Peru to Italy
date: 2021-08-02
journal: J Med Virol
DOI: 10.1002/jmv.27235
sha: e92101cf7afdf430d56b737abb9247ddc67ee990
doc_id: 1055200
cord_uid: ho7f58kc

We report here the introduction of SARS-COV-2 C.37, a variant of interest (VOI) recently renamed "lambda" by WHO, from Peru to Italy. We discuss mutations of concern in this lineage, and evidences for impaired sensitivity to neutralizing antibody-therapeutics and vaccines. This article is protected by copyright. All rights reserved.

To The Editor, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of interest (VOI) deserve special monitoring because of the occurrence of Spike mutations associated with phenotypic implications, such as higher transmissibility or resistance to vaccines or neutralizing antibody-based therapeutics. 1 We report here a 53-years-old female Peruvian immigrant, 3 and in particular, L452R causes resistance to bamlanivimab. 4 Accordingly, "lambda" has been proven to have moderately reduced sensitivity to neutralization by convalescent sera 5 and REGN10987 monoclonal antibody, 5 and slightly reduced sensitivity to BNT162b2, 6 mRNA-1273, 5 and Increased genomic surveillance from South America, especially Peru, will be required to prevent the introduction of SARS-CoV-2 lambda VOI.

Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines

Tracking SARS-CoV-2 variants

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. bioRxiv

Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv

1 currently expanding in Peru and Chile, with a convergent deletion in the ORF1a gene (Δ3675-3677) and a novel deletion in the Spike gene (Δ246-252, G75V, T76I, L452Q, F490S, T859N)